The promise of Bydureon (Exenatide)

This is a promising drug.

youtu.be/fXg_T47Iob4(Not working as expected?)

thelancet.com/journals/lanc...

[WinnieThePoo]

It is a promising drug. It's been promising for a long time. There appears to be a problem with getting a phase 3 trial organised, since it is at least a year since I participated in a live webinar regarding the positive phase 2 trial results. Probably money is the issue. Frustrating, because it appeared very effective, although not without significant complications (mainly nausea, appetite loss, and more seriously weight loss). Just maybe there are other better options competing for resources

[Hidden in reply to WinnieThePoo]

It appears to perhaps partially reverse PD symptoms, does it? Or am I interpreting it wrong?

Also, the effects seems to last only for the duration of the injections and for some time after stopping the injections.

[WinnieThePoo in reply to Hidden]

It isn't supposed to directly help symptoms, although the usual placebo effect issue probably affected data. It prevents the disease progressing. It stops or slows damage to the neurons which get damaged in PD. This may also account for a modest initial symptom improvement. So after you stop taking it, you continue to benefit from not having incurred neuron damage while you took it, but the underlying process which damages the neurons is going to resume right where it left off.

I should say "It may prevent the disease progressing", not "it prevents". The early results were promising but not sufficient to confirm efficacy. Isradipine had similarly promising results at phase 2 and the phase 3 trial found no statistically significant efficacy.